Medical treatment of intermittent claudication: a comparative double-blind study of suloctidil, dihydroergotoxine and placebo.
- 1 January 1976
- journal article
- clinical trial
- Published by Informa Healthcare in Current Medical Research and Opinion
- Vol. 4 (6)
- https://doi.org/10.1185/03007997609111994
Abstract
Forty-five patients suffering from intermittent claudication were admitted to a double-blind non-crossover study. Three groups were constituted at random and treated for 2 months with either 100 mg suloctidil t.i.d. or 1.5 mg dihydroergotoxine methylate t.i.d. or placebo. From the results of measurements of pain-free walking distance and venous occlusion plethysmography recordings, suloctidil was shown to be active and significantly superior to dehydroergotoxine and placebo: in the two latter groups a decrease in calf blood perfusion after 2 months was also noted. The physician's overall assessment of response to treatment showed that suloctidil and dihydroergotoxine were significantly superior to placebo, and that suloctidil was significantly better than dihydroergotoxine.Keywords
This publication has 1 reference indexed in Scilit:
- Potential antilipolytic activity of suloctidilThe Science of Nature, 1975